XML 24 R13.htm IDEA: XBRL DOCUMENT v3.25.3
Intangible Assets
 9 Months Ended
Sep. 30, 2025
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets

Note 7. Intangible Assets

 

The definite-lived intangible assets, to be amortized between 1 and 20 years, balances, and activity for the nine months ended September 30, 2025 and year ended December 31, 2024 consisted of the following:

 

 

      September 30, 2025   December 31, 2024 
   Useful Life   Gross Carrying Amount    Accumulated Amortization    Net Carrying Amount    Gross Carrying Amount    Accumulated Amortization    Net Carrying Amount 
Developed technology assets  20 years  $22,260,000   $5,287,000    16,973,000   $22,260,000   $4,452,000    17,808,000 
Acquired assets  1 -17 years  $325,000   $20,000    305,000   $-   $-    - 
      $22,585,000   $5,307,000   $17,278,000   $22,260,000   $4,452,000   $17,808,000 

 

 

Impact Biomedical, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

 

On February 25, 2025, the Company completed the acquisition of certain assets owned by DSS Pure Air, Inc. (“DSS PureAir”), a related party, for $1,150,000 to be paid by 545,024 shares of the Company’s common stock calculated on a 10-day VWAP. Assets acquired included approximately $325,000 of intellectual property of the Celios air purification system.

 

Amortization expense for the nine months ended September 30, 2025 and 2024 was approximately $855,000 and $835,000, respectively.

 

The following table represents future amortization of developed technologies for the years ending December 31:

 

      
2025  $287,000 
2026  $1,138,000 
2027  $1,136,000 
2028  $1,130,000 
2029  $1,130,000 
Thereafter  $12,457,000